Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S.Y. Shen

MA27.03 Multi-Omic Characterization of TKI-Treated Drug-Tolerant Cell Population in an EGFR-Mutated NSCLC Primary-Derived Xenograft

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Related publications

Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population

Archivos de Bronconeumologia
PulmonaryRespiratory Medicine
2018English

Trastuzumab Emtansine Delays and Overcomes Resistance to the Third-Generation EGFR-TKI Osimertinib in NSCLC EGFR Mutated Cell Lines

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2017English

MA08.03 EGFR-TKI Plus Brain Radiotherapy Versus EGFR-TKI Alone in the Management of EGFR Mutated NSCLC Patients With Brain Metastases: A Meta-Analysis

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.13-26 Impact of Concurrent Tumor Suppressor Gene Mutation on Clinical Outcomes in EGFR Mutated NSCLC Treated With First-Line TKI

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Upfront Radiation Versus EGFR-TKI: Which Is the Best Approach for EGFR-mutated NSCLC Patients With Brain Metastasis?

Translational Cancer Research
Cancer ResearchOncologyRadiologyNuclear MedicineImaging
2017English

Third Generation EGFR TKI Landscape for Metastatic EGFR Mutant Non-Small Cell Lung Cancer (NSCLC)

Expert Review of Anticancer Therapy
OncologyPharmacology
2019English

MALDI Mass Spectrometry Imaging of Erlotinib Administered in Combination With Bevacizumab in Xenograft Mice Bearing B901L, EGFR-mutated NSCLC Cells

Scientific Reports
Multidisciplinary
2017English

MA26.09 Lazertinib, a Third Generation EGFR-TKI, in Patients With EGFR-TKI-Resistant NSCLC: Updated Results of a Phase I/Ii Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Switching From First or Second Generation EGFR-TKI to Osimertinib in EGFR Mutation-Positive NSCLC

Lung Cancer Management
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy